U.S. President Joe Biden said on March 29 that 90 percent of all adults in the United States will be eligible for the coronavirus vaccination by April 19 as he warned about the potential for an upsurge in infections.

Antibody treatments from Eli Lilly and Vir Biotechnology reduced viral load in low-risk Covid-19 patients, results from a mid-stage trial showed on March 29.

GSK and Vir Biotechnology filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage Covid-19 infections, the drugmakers said on March 26.

One dose of Pfizer COVID-19 vaccine offers an immune response similar to that generated by infection and could also offer protection from variants to people who have previously had the virus, a British study said on March 26.

EU leaders voiced frustration on March 25 over a massive shortfall in contracted deliveries of AstraZeneca Covid-19 vaccines, as a third wave of infections surged across Europe.

AstraZeneca released primary analysis showing that the company’s AZD1222 vaccine demonstrated 76 percent efficacy against symptomatic Covid-19, 100 percent efficacy against severe or critical disease and hospitalizations, and 85 percent efficacy against symptomatic Covid-19 in people 65 years and older.

The U.S. Food and Drug Administration approved Melinta Therapeutics’ Kimyrsa (oritavancin) for the treatment of adults with acute bacterial skin and skin structure infections caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus.

A World Health Organization (WHO) expert said on March 15 that the past week saw an 11% increase in Covid-19 cases worldwide, raising concerns that measures to halt the pandemic’s spread may be breaking down just as vaccine distribution picks up.

Sanofi and Translate Bio said on March 12 they had started a human trial of their mRNA Covid-19 vaccine candidate, the French drugmaker’s second vaccine project, which follows a protein-based shot hit by a delay during 2020.

New Covid-19 cases continue to decline in North America, but in Latin America infections are still rising, particularly in Brazil where a resurgence has caused record daily deaths, the Pan American Health Organization (PAHO) warned on March 10.